EU/3/17/1936: Orphan designation for the treatment of gastrointestinal stromal tumours



On 8 November 2017, orphan designation (EU/3/17/1936) was granted by the European Commission to Worldwide Clinical Trials Limited, United Kingdom, for 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea (also known as DCC-2618) for the treatment of gastrointestinal stromal tumours.

The sponsorship was transferred to Pharma Gateway AB, Sweden, in May 2018.

The sponsorship was transferred to Deciphera Pharmaceuticals (Netherlands) B.V., Netherlands, in July 2020.

The sponsor’s address was updated in August 2021.

Ripretinib has been authorised in the EU as Qinlock since 18 November 2021.

Key facts

Active substance
Intended use
Treatment of gastrointestinal stromal tumours
Orphan designation status
EU designation number
Date of designation

Deciphera Pharmaceuticals (Netherlands) B.V.
Atrium Building Floor 4th
Strawinskylaan 3051
1077 ZX
Tel: +31 20 301 2200


Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Qinlock at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.

More information is available in the PDF icon orphan medicine assessment report .

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating